Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 5/20 | 0.44 |
| ▸ | CTSB | P07858 | 3/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.41 |
| ▸ | HPGDS | O60760 | 5/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | PYGL | P06737 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6426039 | 0.90 | CAPN1 (0.49) | CAPN1CTSBROCK2ROCK1HPGDS | |
| SCHEMBL5031117 | 0.85 | CAPN1 (0.51) | CAPN1CTSBROCK2ROCK1HPGDS | |
| SCHEMBL5032420 | 0.83 | CAPN1 (0.50) | CAPN1CTSBROCK2ROCK1HPGDS | |
| SCHEMBL5030209 | 0.83 | CAPN1 (0.45) | CAPN1CTSBROCK2ROCK1HPGDS | |
| SCHEMBL13927729 | 0.83 | CAPN1 (0.49) | CAPN1CTSBROCK2ROCK1HPGDS | |
| SCHEMBL6426415 | 0.81 | CAPN1 (0.48) | CAPN1CTSBROCK2ROCK1HPGDS | |
| SCHEMBL6428387 | 0.81 | ROCK2 (0.34) | ROCK2ROCK1 | |
| SCHEMBL4145364 | 0.80 | PIM1 (0.36) | — | |
| SCHEMBL4145370 | 0.80 | PIM1 (0.36) | — | |
| SCHEMBL6428453 | 0.80 | CAPN1 (0.46) | CAPN1CTSBROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | CAPN1 4435/4885CTSB 3688/4885ROCK2 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.